These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29666786)

  • 1. Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells.
    LaMarca EA; Powell SK; Akbarian S; Brennand KJ
    Front Pediatr; 2018; 6():82. PubMed ID: 29666786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling common and rare genetic risk factors of neuropsychiatric disorders in human induced pluripotent stem cells.
    Muhtaseb AW; Duan J
    Schizophr Res; 2022 Apr; ():. PubMed ID: 35459617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating CRISPR Engineering and hiPSC-Derived 2D Disease Modeling Systems.
    Rehbach K; Fernando MB; Brennand KJ
    J Neurosci; 2020 Feb; 40(6):1176-1185. PubMed ID: 32024766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas9-Edited SNCA Knockout Human Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons and Their Vulnerability to Neurotoxicity.
    Inoue S; Nishimura K; Gima S; Nakano M; Takata K
    Biol Pharm Bull; 2023; 46(3):517-522. PubMed ID: 36858582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of mitophagy in human iPSC-derived cardiomyocytes.
    Yang M; Fu JD; Zou J; Sridharan D; Zhao MT; Singh H; Krigman J; Khan M; Xin G; Sun N
    Autophagy; 2022 Oct; 18(10):2481-2494. PubMed ID: 35220905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms.
    Choi DK; Kim YK; HoonYu J; Min SH; Park SW
    Prog Mol Biol Transl Sci; 2021; 181():271-287. PubMed ID: 34127196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform.
    Garcia-Leon JA; Vitorica J; Gutierrez A
    Future Med Chem; 2019 Jun; 11(11):1305-1322. PubMed ID: 31161803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clustered regularly interspaced short palindromic repeats as an advanced treatment for Parkinson's disease.
    Mehmood A; Ali W; Din ZU; Song S; Sohail M; Shah W; Guo J; Guo RY; Ilahi I; Shah S; Al-Shaebi F; Zeb L; Asiamah EA; Al-Dhamin Z; Bilal H; Li B
    Brain Behav; 2021 Aug; 11(8):e2280. PubMed ID: 34291612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pluripotent Stem Cells to Model Degenerative Retinal Diseases: The RPE Perspective.
    Dalvi S; Galloway CA; Singh R
    Adv Exp Med Biol; 2019; 1186():1-31. PubMed ID: 31654384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient generation of hiPSC neural lineage specific knockin reporters using the CRISPR/Cas9 and Cas9 double nickase system.
    Li S; Xue H; Long B; Sun L; Truong T; Liu Y
    J Vis Exp; 2015 May; (99):e52539. PubMed ID: 26065872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-based functional evaluation of schizophrenia risk variants.
    Rajarajan P; Flaherty E; Akbarian S; Brennand KJ
    Schizophr Res; 2020 Mar; 217():26-36. PubMed ID: 31277978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing Drug Discovery for Neurological Disorders Using iPSC-Derived Neural Organoids.
    Costamagna G; Comi GP; Corti S
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling.
    Li W; Chen S; Li JY
    Prog Neurobiol; 2015 Nov; 134():161-77. PubMed ID: 26408505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of kidney organoids derived from human pluripotent stem cells.
    Kim YK; Nam SA; Yang CW
    Korean J Intern Med; 2018 Jul; 33(4):649-659. PubMed ID: 29961307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Induced Pluripotent Stem Cell NEUROG2 Dual Knockin Reporter Lines Generated by the CRISPR/Cas9 System.
    Li S; Xue H; Wu J; Rao MS; Kim DH; Deng W; Liu Y
    Stem Cells Dev; 2015 Dec; 24(24):2925-42. PubMed ID: 26414932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics.
    Sen T; Thummer RP
    Neurotox Res; 2022 Oct; 40(5):1597-1623. PubMed ID: 36044181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studying Kidney Disease Using Tissue and Genome Engineering in Human Pluripotent Stem Cells.
    Garreta E; González F; Montserrat N
    Nephron; 2018; 138(1):48-59. PubMed ID: 28988229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reprogramming of HUVECs into induced pluripotent stem cells (HiPSCs), generation and characterization of HiPSC-derived neurons and astrocytes.
    Haile Y; Nakhaei-Nejad M; Boakye PA; Baker G; Smith PA; Murray AG; Giuliani F; Jahroudi N
    PLoS One; 2015; 10(3):e0119617. PubMed ID: 25789622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.